Co-founder and MD Roby Zamer said the company was developing medicines that leveraged its proprietary medicinal cannabis formula through clinical trials in Israel and Australia, enabling future medical product sales across the globe following regulatory approvals.
Two cannabinoid medicinal products
The vertically integrated, European-based bio-pharma company has two investigational medicinal products targeting refectory epilepsy and dementia as well as Alzheimer’s disease.
These include CannEpil®, an oral oil solution treatment for refractory epilepsy and CogniCann®, an oral spray for relief of dementia symptoms.
The products are already available in Australia, New Zealand, the UK, Ireland and Brazil with a rapidly growing patient base as the company continues to deliver cannabinoid medicines to patients.
MGC Pharmaceuticals also has a range of phytotherapeutic products under the Mercury MGC Pharma brand name, which enables medical professionals to prescribe as they see best suited for their patient.
The product line ranges form pure, whole plant CBD extract through to a high-THC formulation.
Currently, the company has a Slovenian-based GMP facility which has the capacity to manufacture up to 12,000 prescriptions products per month.
Plans are in place to build a full, large scale production facility in Malta.
Effectiveness of ArtemiC on human immune cells
The company recently confirmed the effective immunological activity for the use of ArtemiC as an immune-modulatory agent for the treatment of COVID-19.
Further studies are underway and planned to augment these initial findings to evaluate the preferable ratios between the active ingredients.
MGC is awaiting the first interim results from the COVID-19 infected patients from the Phase II randomised, double-blind clinical trial underway in Israel, which are expected to be finalised shortly.